Treatment of Pancreatic Cancer Stockton CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Ronald Alessio Allison, MD
(209) 943-2107
415 E Harding Way Ste H
Stockton, CA
Specialties
Urology, Family Medicine
Gender
Male
Languages
German, Spanish
Education
Medical School: Columbia Univ Coll Of Physicians And Surgeons, New York Ny 10032
Graduation Year: 1967
Hospital
Hospital: San Joaquin Gen Hosp, French Camp, Ca; Dameron Hosp, Stockton, Ca; Sutter Tracy Comm Hosp, Tracy, Ca
Group Practice: Ronald Allison Inc

Data Provided by:
Prithipal Singh Sethi, MD
(209) 941-0371
534 E Maple St
Stockton, CA
Specialties
Urology
Gender
Male
Education
Medical School: St Louis Univ Sch Of Med, St Louis Mo 63104
Graduation Year: 1999

Data Provided by:
Peter James Garbeff, MD
(209) 941-0371
534 E Maple St
Stockton, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Southern Ca Sch Of Med, Los Angeles Ca 90033
Graduation Year: 1977

Data Provided by:
Ronald C A Allison, MD FACS
(209) 943-2107
415 E Harding Way
Stockton, CA
Gender
Male
Education
Medical School: Columbia
Graduation Year: 1967

Data Provided by:
Melanie Gayle Parker, MD
(209) 476-3734
7373 West Ln
Stockton, CA
Specialties
Urology
Gender
Female
Education
Medical School: Med Coll Of Ga Sch Of Med, Augusta Ga 30912
Graduation Year: 1987

Data Provided by:
Peter Garbeff
(209) 941-0371
534 E Maple St
Stockton, CA
Specialty
Urology

Data Provided by:
Prithipal S Sethi
(209) 464-3627
1805 N California St
Stockton, CA
Specialty
Urology

Data Provided by:
Lawrence D Hildebrand, MD
(209) 941-0371
534 E Maple St
Stockton, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Manitoba, Fac Of Med, Winnipeg, Man, Canada
Graduation Year: 1960
Hospital
Hospital: Dameron Hosp, Stockton, Ca; St Josephs Med Ctr, Stockton, Ca
Group Practice: Maple Street Urology Med Group

Data Provided by:
Kurt Rogers Roemer, MD
(209) 943-2107
534 E Maple St
Stockton, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ms Sch Of Med, Jackson Ms 39216
Graduation Year: 1979
Hospital
Hospital: St Josephs Med Ctr, Stockton, Ca
Group Practice: Maple Street Urology Med Group

Data Provided by:
Melanie E Parker
(209) 476-2000
7373 West Ln
Stockton, CA
Specialty
Urology

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com